CLEVELAND--(BUSINESS WIRE)--Cleveland HeartLab LLC (CHL) today announced the appointment of Glenn A. Gershon as vice president of clinical laboratory operations and research and development.
Mr. Gershon was most recently vice president of laboratory operations, quality and regulatory affairs, and research and development at Athena Diagnostics Inc., a leading specialty clinical reference laboratory with a catalog of nearly 400 tests. While at Athena, Mr. Gershon significantly improved laboratory efficiency, reducing the lab’s turnaround time and expanding its operating margin. He managed the successful launch of 30 new Athena tests in 2009 and 35 in 2010.
Mr. Gershon spent nearly 14 years at Abbott Diagnostics, where he led the development and launch of a number of important in vitro diagnostic tests. He also served as business team manager for a key Abbott Diagnostics unit and manager of technical product development.
After his service at Abbott Diagnostics, Mr. Gershon was executive director of technical support and field quality for the former Chiron Diagnostics immunodiagnostics business and vice president of quality assurance for the worldwide laboratory testing segment of Bayer Corp.’s Diagnostics Division after its acquisition of Chiron Diagnostics.
“We are delighted to welcome Glenn to Cleveland HeartLab’s management team,” said Jake Orville, president and chief executive of CHL. “Glenn’s operations, quality and product development experience with top notch companies in the clinical laboratory industry, particularly Athena Diagnostics, will be critical to the ongoing execution of Cleveland HeartLab’s strategy, which has driven outstanding growth for the company during the past 12 months.”
“I’m excited to being joining the Cleveland HeartLab team at such an important time in the company’s development,” Mr. Gershon said. “CHL is well positioned to be the leading specialty clinical reference laboratory and cardiovascular disease management company. I’m looking forward to helping to lead the company to continued growth and outstanding performance that not only benefits customers and investors, but cardiovascular patients, as well.”
About Cleveland HeartLab
Cleveland HeartLab LLC is a specialty clinical laboratory and disease management company focused on offering a robust menu of propriety diagnostic tests based on unique molecular biomarkers. CHL operates a CLIA-certified and CAP-accredited clinical laboratory located on the main campus of Cleveland Clinic. The company has developed a panel of tests that physicians use in the management and reduction of inflammation in their patients. CHL runs a research & development laboratory where next-generation cardiovascular disease biomarkers are being developed for use by physicians through CHL’s clinical laboratory. This valuable pipeline of tests is part of an exclusive intellectual property portfolio that targets large, under-addressed markets. Several of these tests have been licensed from Cleveland Clinic. For more information about Cleveland HeartLab, please visit the company’s web site at www.clevelandheartlab.com.